These Analysts Revise Their Forecasts On Stoke Therapeutics After Q2 Results - Stoke Therapeutics (NASDAQ

Stoke Therapeutics (STOK) reported mixed Q2 results with losses of 93 cents per share and sales of $9.325 million. Analysts have mixed opinions.

Raccontata dabenzinga.com